Vanguard Asset Management
JBIO

Vanguard Asset Management’s Jade Biosciences JBIO Stock Holding History

Vanguard Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813K Buy
+36,587
New +$763K ﹤0.01% 1989

Other funds holding JBIO

JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Asset Management's JBIO Position: Q2 2026 in Review

Vanguard Asset Management opened a new position in Jade Biosciences (JBIO) in Q2 2026: 36,587 shares worth $813K. The stake represents ﹤0.01% of the portfolio and ranks #1989 among its holdings.

141 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Vanguard Asset Management held 36,587 shares of Jade Biosciences worth $813K as of Q2 2026.
  • Jade Biosciences was a new Vanguard Asset Management position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1989 holding.
  • 141 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.